Vnitr Lek 2023, 69(4):261-264 | DOI: 10.36290/vnl.2023.049

Dapagliflozin in the treatment of heart failure with preserved ejection fraction

Terézia Švarcová

Edumed, s. r. o., I. interní kardioangiologická klinika FN Hradec Králové

We present obese patient with numerous comorbidities in this case report, who's treatment of heart failure with preserved ejection fraction (HF PEF) has been managed in our office for several years. The treatment was limited by the patient's comorbidities (renal failure, obesity, atrial fibrillation, anemia) and by the patient's preferences. The patient's trust and cooperation is essential, as this case report confirms. The patient paid for empagliflozin which he did not tolerate. The patient however was willing to try dapagliflozin at his own expense. Dapaglifllozin was well tolerated by the patient and improved his quality of life significantly. Intolerance of one drug does not necessarily mean intolerance of the whole class. Another member of the same drug class could be beneficial as shown by this case report.

Keywords: polymorbid patient, heart failure with preserved ejection fraction, patient reimbursement drug, gliflozins.

Accepted: May 31, 2023; Published: June 22, 2023  Show citation